Akebia TherapeuticsSTU:AX9 -0.35%50 Days Inventory is 105.46 as of Mar. 2026, which is 13% below its 10-year median of 121.20. GuruFocus rates STU:AX9 with a GF Score™ of 50/100 and a GF Value™ of €1.15 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 916 Drug Manufacturers companies, Akebia Therapeutics ranks better than 61.03% on this metric.
The historical rank and industry rank for Akebia Therapeutics's Days Inventory or its related term are showing as below:
STU:AX9'
s Days Inventory Range Over the Past 10 Years
Min: 91.7 Med: 121.2 Max: 5368.1
Current: 138.45
During the past 13 years, Akebia Therapeutics's highest Days Inventory was 5368.10. The lowest was 91.70. And the median was 121.20.
STU:AX9's Days Inventory is ranked better than 61.03% of 916
companies
in the Drug Manufacturers industry
Industry Median: 164.43
vs STU:AX9: 138.45
Akebia Therapeutics's Days Inventory
declined
from Mar. 2025 (218.42) to Mar. 2026 (105.46).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Akebia Therapeutics's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.87.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Akebia Therapeutics's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.27.
Akebia Therapeutics (STU:AX9) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Akebia Therapeutics's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Akebia Therapeutics's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Akebia Therapeutics Days Inventory Related Terms
Akebia Therapeutics Days Inventory Historical Data
* Premium members only.
The historical data trend for Akebia Therapeutics's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:AX9 vs TKNO, ORGO, SIGA: Days Inventory Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Akebia Therapeutics's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Akebia Therapeutics Days Inventory vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Akebia Therapeutics's Days Inventory distribution charts can be found below:
* The bar in red indicates where Akebia Therapeutics's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Akebia Therapeutics (STU:AX9) has a Days Inventory of 105.46 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Akebia Therapeutics and its competitors. This is 13% below median its historical median of 121.20. Over the past decade, Akebia Therapeutics' Days Inventory has ranged from 91.70 to 5,368.10. According to the industry distribution chart, Akebia Therapeutics ranks #357 out of 916 companies in the Drug Manufacturers industry, placing it in the top 39%.
Is Akebia Therapeutics' Days Inventory too high?
Akebia Therapeutics' current Days Inventory of 105.46 is 13% below median its 10-year median of 121.20. Over the past 10 years, this metric has ranged from a low of 91.70 to a high of 5,368.10. The Drug Manufacturers industry median Days Inventory is 164.43. Akebia Therapeutics' value of 105.46 is 35.9% below this industry median. Based on the distribution chart, Akebia Therapeutics ranks #357 out of 916 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Akebia Therapeutics has a GF Score™ of 50/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Akebia Therapeutics' Days Inventory compare to TKNO and ORGO?
According to the Drug Manufacturers industry distribution chart, Akebia Therapeutics ranks #357 out of 916 companies for Days Inventory. This puts Akebia Therapeutics in the upper half of its industry. The industry median Days Inventory is 164.43. Akebia Therapeutics' value of 105.46 is 35.9% below this benchmark. Historically, Akebia Therapeutics' own Days Inventory has ranged from 91.70 to 5,368.10 over the past decade. While the company's 10-year median is 121.20 vs. the industry median of 164.43, Akebia Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Drug Manufacturers company?
The median Days Inventory among Drug Manufacturers companies is 164.43, based on 916 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Akebia Therapeutics's current Days Inventory of 105.46 is 35.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Akebia Therapeutics and its competitors. For the Drug Manufacturers industry, the median Days Inventory is 164.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Akebia Therapeutics's current Days Inventory is 105.46, which is 13% below median its own 10-year median of 121.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akebia Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Akebia Therapeutics (STU:AX9) is currently considered Modestly Undervalued. The stock's GF Value™ is €1.15, compared to a current price of €0.98 — trading 15.2% below its estimated fair value. The current Days Inventory is 105.46, which is 13% below median its 10-year median of 121.20 and 35.9% below the Drug Manufacturers industry median of 164.43. Akebia Therapeutics' overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Akebia Therapeutics (STU:AX9), the current Days Inventory is 105.46 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Akebia Therapeutics (STU:AX9) Overvalued in 2026?
Based on GuruFocus' analysis, Akebia Therapeutics stock appears to be undervalued.
The current stock price of €0.98 is trading 15.2% below its estimated GF Value™ of €1.15.
GuruFocus considers Akebia Therapeutics to be Modestly Undervalued.
Key valuation signals for STU:AX9:
Days Inventory: 105.46 (13% below median its 10-year median of 121.20)
GF Value™: €1.15 vs. price of €0.98 (15.2% below fair value)
Industry Position: 35.9% below the Drug Manufacturers median (#357 of 916)
No single metric tells the full story. See the STU:AX9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
50GF Score
Get the complete analysis for STU:AX9
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:AX9 has been successfully added to your 
